Gynecologic assessment of 19 adult females with cartilage-hair hypoplasia – high rate of HPV positivity

Table 3 Antral follicle count and hormone levels in 14 premenopausal women with cartilage-hair hypoplasia

Study subject	Age group	Current hormonal treatment	Day of menstrual cycle	AFC (N)	FSH (IU/L)	LH (IU/L)	E2 (nmol/L)	AMH (ug/L)
1	19–30	CC	–	18	3.7	2.3	0.179	1.97
2	19–30		9	12	5	3.8	0.643	0.94
3	19–30		14	15	14	25.2	0.434	2.29
4	19–30		26	18	5.7	7.2	0.316	4.66
5	19–30	PP	–	7^a	7.3	4.9	0.07	3.68
6	19–30		14	10	2	0.9	0.264	1.87
7	19–30		20	16	1.8	0.6	0.49	*1.39*
8	31–40		5	14	5.6	4.9	0.32	5.68
9	31–40		17	10	6	12.5	0.579	< 0.2
10	31–40		19	3^a	2.7	1.6	0.423	0.63
11	41–50	PP	–	4	5	1.6	0.081	0.22
12	41–50		20	9	3.1	3.8	0.336	1.34
13	41–50		t.a., am	5	8.5	4.8	0.231	< 0.2
14	41–50		4 mo am	1	68.4	40.9	0.046	< 0.2

AFC antral follicle count, AMH anti-Müllerian hormone, CC combined contraception, E2 estradiol, FSH follicle-stimulating hormone, LH luteinizing hormone, mo months, N number, PP progestin-only pill, am amenorrhea; t.a. endometrium thermoablation done; ^aDetected from one ovary only. Numbers in bold represent values below normal age-specific values and numbers in italics low normal age-specific values. AMH values detected by two different methods are converted mathematically to correspond each other as described in detail in Methods. Ages are given as age groups to ensure anonymity

ISSN: 1750-1172